pCDNA3-HA-human MYCN Citations (6)

Originally described in: The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.
Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, Walz S, Murphy BL, Youn YH, Han YG, Eilers M, Roussel MF Cancer Cell. 2016 Jan 11;29(1):5-16. doi: 10.1016/j.ccell.2015.12.003. PubMed Journal

---

Articles Citing pCDNA3-HA-human MYCN

Articles
Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1). Noguchi K, Dincman TA, Dalton AC, Howley BV, McCall BJ, Mohanty BK, Howe PH. J Biol Chem. 2018 Jul 20;293(29):11401-11414. doi: 10.1074/jbc.RA118.003616. Epub 2018 Jun 5. PubMed
Targeting the Difficult-to-Drug CD71 and MYCN with Gambogic Acid and Vorinostat in a Class of Neuroblastomas. Bishayee K, Habib K, Sadra A, Huh SO. Cell Physiol Biochem. 2019;53(1):258-280. doi: 10.33594/000000134. PubMed
MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. Yasukawa K, Liew LC, Hagiwara K, Hironaka-Mitsuhashi A, Qin XY, Furutani Y, Tanaka Y, Nakagama H, Kojima S, Kato T, Ochiya T, Gailhouste L. Cancer Sci. 2020 Mar;111(3):869-880. doi: 10.1111/cas.14292. Epub 2020 Jan 25. PubMed
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A. Int J Mol Sci. 2021 Dec 4;22(23). pii: ijms222313122. doi: 10.3390/ijms222313122. PubMed
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Xu P, Yang JC, Chen B, Ning S, Zhang X, Wang L, Nip C, Shen Y, Johnson OT, Grigorean G, Phinney B, Liu L, Wei Q, Corey E, Tepper CG, Chen HW, Evans CP, Dall'Era MA, Gao AC, Gestwicki JE, Liu C. Nat Commun. 2024 Aug 5;15(1):6626. doi: 10.1038/s41467-024-50459-x. PubMed
Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Dhar SS, Brown C, Rizvi A, Reed L, Kotla S, Zod C, Abraham J, Abe JI, Rajaram V, Chen K, Lee MG. Cell Rep. 2025 May 27;44(5):115619. doi: 10.1016/j.celrep.2025.115619. Epub 2025 Apr 25. PubMed

If you have published an article using this material, please email us at to have your article added to this page.